I am the Founder and CEO of MedicSense Ltd., a Clinical and Regulatory Affairs consultancy firm that specializes in assisting companies to navigate through the international clinical and regulatory maze.
With more than twenty years of experience, I specialize in developing company-tailored clinical and regulatory strategies, meet technical and regulatory demands for your products, guiding you through specific technological requirements and best practices for the collection of clinical data. My previous experience includes managing clinical and regulatory affairs departments in both well-established and start-up companies.
Adam is a veteran sales and marketing executive, award-winning brand builder and cannabis industry innovator, known for building high performing teams and driving significant business results.
Adam currently serves as the Chief Commercial Officer at Westleaf Inc, a publicly traded, vertically integrated cannabis company focusing on cultivation, extraction and wholly owned retail cannabis stores. In this role, Adam leads all sales, marketing and business development initiatives, along with the company’s strategy and execution of its retail roll-out in Western Canada.
As one of the first to join the company, Adam has been responsible for the ideation, development, and launch of Westleaf’s award-winning retail brand, Prairie Records. Adam is also responsible for developing the company’s premium proprietary cannabis product lines and distribution strategy.
As an early adopter of the cannabis industry, Adam brings over 10 years of experience in regulated consumer-packaged good sales, marketing and business development. Prior to Westleaf, Adam served as Vice President of Specialty Sales at Labatt Breweries of Canada, where he was responsible for over $70 million in revenue and overall volume and revenue growth in eight major urban centres across Canada. Prior to that, Adam served as Senior Manager of Finance at Labatt, where he led the business integration and brand expansion for the acquisitions of Mill Street Brewery and Mark Anthony Brands.
Dennis is a life sciences executive bringing over 18 years of experience in Clinical Research, Technology, and Operations. Offering broad achievements in the Pharmaceutical industry in clinical operations, portfolio management, vendor qualification, relationship management and eClinical solutions. He possesses focused leadership skills to drive results in highly competitive markets.
Having more than 20 years of experience in information technology enterprise implementations, Nicos has been instrumental in Dot.Cy’s own transformation by converting a general Microsoft Dynamics 365 consulting company into a leader in hospitality, travel and leisure business automation solutions by leveraging Microsoft Dynamics 365 and Microsoft Azure technologies. Nicos is currently working with Dot.Cy’s internal product teams and clients in the development of guest-centric, cloud-based, innovative business and operational solutions for the hospitality industry, leveraging Microsoft Dynamics 365 enterprise features and solutions ecosystem.
Miriama is a General Manager for Marketing at Arti Grafiche Julia. Started in 2019, brings a strong semiconductor background utilizing years of experience in NXPs MIFARE.
Nowadays, the team around Miriama focuses on making ECO RFID cards accessible to industries to minimize their ecological footprint while maintaining cost and performance excellence.
Aurélien Gilot is a Technical Sales Manager and food engineer. He has been working in clinical field studies for 5 years (efficacy testing for cosmetic and ingredients) In 20154, he came back to the food industry with GNT. At GNT he is responsible for the following fields:
- Dairy Industry and Fruit Prep manufacturers worldwide
- Flavor houses and food supplements in France
Dr. Setnik has been working in the area of clinical drug development and abuse potential (AP) assessment since 2005. Dr. Setnik is currently the Chief Scientific Officer at Altasciences and an Adjunct Professor at the University of Toronto (Department of Pharmacology and Toxicology). Dr. Setnik earned her doctorate degree in Pharmacology and the Collaborative Program in Neuroscience from the University of Toronto in 2005. In her former role as Vice President of Scientific & Medical Affairs at INC Research/inVentiv Health (Early Phase), she was responsible for scientific input on early phase clinical trials and in strategic initiatives in business growth and development. In her previous role as Senior Director, Clinical Sciences (King Pharmaceuticals and Pfizer, Inc), Dr. Setnik lead the clinical development, regulatory filing, and lifecycle management, including abuse potential evaluation, of several pain compounds including abuse deterrent opioid formulations. In her previous role as a Research Scientist (formerly Ventana / Decisionline Clinical Research, Toronto, Canada), Dr. Setnik was responsible for providing scientific input on various specialty phase I-II clinical trials including abuse potential studies for CNS drugs. Dr. Setnik has published numerous research articles in internationally recognized peer-reviewed journals and has presented at over 200 scientific meetings and conferences. In addition, she is the Managing Director and Clinical subgroup lead Cross Company Abuse Liability Council and chair of the Clinical Pharmacology Community of the Drug Information Association (DIA). Dr. Setnik is also an active member and participant in several congresses including the College on Problems of Drug Dependence. She has also been actively engaged in many aspects of abuse potential assessment including development of patient reported outcome instruments and contributing to post-marketing surveillance studies.
